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Purpose: The rationale for hypofractionated radiotherapy in the treatment of prostate can-
cer is based on the modern understanding of radiobiology and advances in stereotactic
body radiotherapy (SBRT) techniques. Whole-pelvis irradiation combined with SBRT boost
for high-risk prostate cancer might escalate biologically effective dose without increasing
toxicity. Here, we report our 4-year results of SBRT boost for high-risk localized prostate
cancer.
Methods and Materials: From October 2009 to August 2012, 41 patients newly diag-
nosed, high-risk or very high-risk (NCCN definition) localized prostate cancer were treated
with whole-pelvis irradiation and SBRT boost. The whole pelvis dose was 45 Gy (25 frac-
tions of 1.8 Gy). The SBRT boost dose was 21 Gy (three fractions of 7 Gy). Ninety percent
of these patients received hormone therapy.The toxicities of gastrointestinal (GI) and gen-
itourinary (GU) tracts were scored by Common Toxicity Criteria Adverse Effect (CTCAE
v3.0). Biochemical failure was defined by Phoenix definition.
Results: Median follow-up was 42 months. Mean PSA before treatment was 44.18 ng/ml.
Mean PSA level at 3, 6, 12, 18, and 24 months was 0.94, 0.44, 0.13, 0.12, and 0.05 ng/ml,
respectively. The estimated 4-year biochemical failure-free survival was 91.9%. Three bio-
chemical failures were observed. GI and GU tract toxicities were minimal. No grade 3 acute
GU or GI toxicity was noted. During radiation therapy, 27% of the patient had grade 2 acute
GU toxicity and 12% had grade 2 acute GI toxicity. At 3 months, most toxicity scores had
returned to baseline. At the last follow-up, there was no grade 3 late GU or GI toxicity.
Conclusions: Whole-pelvis irradiation combined with SBRT boost for high-risk localized
prostate cancer is feasible with minimal toxicity and encouraging biochemical failure-free
survival. Continued accrual and follow-up would be necessary to confirm the biochemical
control rate and the toxicity profiles.
Keywords: prostate cancer, high-risk prostate cancer, stereotactic body, radiotherapy, SBRT boost, whole-pelvis
radiotherapy, CyberKnife, Rapidarc
INTRODUCTION
Prostate cancer is not only the most common male malignancy
in the US (1) and the rest of the Western world but also a rising
health problem in Asia (2, 3). It is worth noting that before or in
the early PSA era (late 1980s and early 1990s) patients presented
with higher volume disease than in the current PSA screening era
(4, 5). However, the current estimates indicate that high-risk dis-
ease accounts for 15% of all prostate cancer diagnoses in the US (6)
and even higher in the low-PSA screening regions, like Asia (7). In
a Japanese institutional database, approximately 50% of prostate
cancer patients had high-risk disease at diagnosis (8).
Generally, patients with high-risk prostate cancer have a signif-
icant chance of developing systemic or local recurrence and are at
higher risk for symptoms or death from the disease (9). Patients of
high-risk prostate cancer have a more aggressive form of the dis-
ease with the higher possibility of direct extension and/or locore-
gional micrometastases and require a more intensive approach of
treatment to maintain a normal life expectancy.
According to the modern understanding of radiobiology,
prostate cancer is more sensitive to large doses per fraction. Accu-
mulating evidence has demonstrated that the α/β ratio of prostate
cancer is lower than that of other common tumors and late-
responding tissue (ranges from 1.2 to 3.1 Gy) (10–13); that is, using
a hypofractionated radiotherapy schema may improve the bio-
chemical control of prostate cancer without increasing toxicities
associated with late-responding tissues (14).
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The hypofractionated boost is used to supplement a course of
conventionally fractionated external-beam radiotherapy (EBRT)
designed to escalate the biological dose to a larger volume encom-
passing the microscopic disease adjacent to the prostate and
seminal vesicles. High-dose-rate (HDR) brachytherapy using as
a hypofractionated boost to EBRT has shown promising results
(15–19).
The past few years have seen significant advances in radio-
therapy techniques and stereotactic body radiotherapy (SBRT) is
now at the forefront of innovation. The major features of SBRT
are the accurate delivery of high doses to the target area and the
rapid tapering of the dose away from the target area, using either
a single or limited number of fractions. The SBRT boost in con-
junction with EBRT in the treatment of prostate cancer is based
on the clinical success of HDR brachytherapy boost, the modern
understanding of radiobiology for prostate cancer, and advances
in radiotherapy technique. Here, we report our early results of
whole-pelvis radiotherapy (WPRT) and SBRT boost for high-risk
localized prostate cancer.
MATERIAL AND METHODS
PATIENT SELECTION
From October 2009 to August 2012, patients newly diagnosed
with high-risk localized prostate cancer and treated with WPRT
and SBRT boost were enrolled in this retrospective analysis. All
patients had histologically confirmed primary adenocarcinoma
of the prostate. Stage was determined by physical exam, bone
scan, and MRI or CT scans. None of these patients had received
any other local or systemic primary treatment of prostate can-
cer when enrolled in this treatment protocol, except neoadjuvant
hormone therapy (NHT). Prior transurethral resection of the
prostate (TURP) for urinary symptom relief was allowed. All
the patients were classified as high-risk or very high-risk group,
defined by National Comprehensive Cancer Network (NCCN)
guidelines with the presence of any one of the following high-
risk factors: pre-biopsy PSA≥ 20 ng/ml, Gleason score 8–10, and
clinical stage T3. The institutional review board approved this
retrospective analysis.
RADIOTHERAPY PREPARATION
Patients underwent transrectal implantation of four fiducials
before WPRT, with two seeds placed at the prostate apex and two
at the base. CT simulation was performed 1 week after fiducial
implantation to account for possible fiducial migration. A custom
vacuum cushion, knee support, and other devices were applied
to all patients for immobilization. WPRT and SBRT boost treat-
ment planning were based on the thin-slice CT images (1–2 mm in
thickness). MRI fusion was utilized as a supplement for anatomical
contour delineation.
WHOLE-PELVIS RADIOTHERAPY TREATMENT PLANNING AND
DELIVERY
Target volume delineation
The prostate gland, the entire seminal vesicles (with or without
invasion), and the area of radiographic extracapsular extension
were defined as the clinical target volume (CTV) 1. CTV 2 included
the four anatomical pelvic node groups (the external and inter-
nal iliac nodes, the presacral nodes, and the obturator nodes),
following the RTOG consensus (20). The planning target volume
(PTV) 1 was extended 7 mm beyond the CTV1 in all directions,
except in the posterior direction, wherein it was extended 5 mm.
The pelvic node PTV (PTV2) was extended 7 mm in all directions.
Organs at risk
The rectum was contoured as a solid organ from the bottom of
the ischium to the sigmoid flexure. The entire bladder was con-
toured. The small bowel was contoured as the peritoneal cavity
and the upper boundary was 1 cm higher than PTV2. For WPRT,
the rectum constraint was less than 17% of the rectal volume to
receive more than 42 Gy (V42< 17%). Urinary bladder constraint
was less than 40% of the urinary bladder volume to receive more
than 40 Gy (V40< 40%). Small bowel constraints were less than
0–1 cm3 of the small bowel volume to receive more than 52–54 Gy
(V54–52< 0–1 cm3) and mean small bowel dose less than 23.5 Gy
(mean dose< 23.5 Gy).
Basic treatment plan criteria for WPRT
The prescription dose of WPRT was 45 Gy and was administered
in 25 fractions. A minimum of 95% of the prescription dose was
assured to cover 100% of the PTV.
All WPRT treatment plans were generated on Varian Eclipse
treatment planning system (version 8.6.10, Varian Medical Sys-
tems, Palo Alto, CA, USA) (Figures 1A,B). The optimization
and dose calculation were similar to the previous description
(21). WPRT was delivered by RapidArc technique with daily
image-guidance (two arcs, Varian Clinac iX).
SBRT BOOST TREATMENT PLANNING AND DELIVERY
Target volume delineation
The prostate gland, the entire seminal vesicles (with or without
invasion), and area of radiographic extracapsular extension were
defined as CTV1, which was the same as in the WPRT treatment
plans. For SBRT boost, the planning target volume (PTV) was
extended 5 mm beyond the CTV in all directions, except in the
posterior direction, wherein it was extended 3 mm.
Organ at risk
The rectum, urinary bladder, and penile bulb were contoured.
For SBRT boost, the rectum constraints were less than 1 cm3 of
the rectum volume to receive more than 20 Gy (V20< 1 cm3)
and less than 17% of the rectal volume to receive more than
14.5 Gy (V14.5< 17%). Urinary bladder constraints were less than
5 cm3 of the urinary bladder volume to receive more than 21 Gy
(V21< 5 cm3) and less than 25% of the urinary bladder volume to
receive more than 14.5 Gy (V14.5< 25%). Penile bulb constraint
was less than 50% of the penile bulb volume to receive more than
16.5 Gy (V16.5< 50%).
Basic treatment plan criteria for SBRT boost
The prescription dose of SBRT boost was 21 Gy in three fractions.
A minimum of 95% of the prescription dose was made sure to
cover 95% of the PTV after prescription to the 80% (or higher)
isodose line. All SBRT boost treatment plans were generated on
MultiPlan (version 2.2.0, Accuracy Incorporated, Sunnyvale, CA,
USA) (Figures 2A,B). The optimization and dose calculation were
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FIGURE 1 | Isodose curves (A) and dose–volume histogram (B) of whole pelvis radiotherapy for the applied RapidArc plan in the particular patient.
(A) The region of the prescription dose (45 Gy), pink color wash; CTV1, red solid line.
FIGURE 2 | Isodose curves (A) and dose–volume histogram (B) of SBRT boost for the applied CyberKnife in the particular patient. (A) The prescription
dose (21Gy), blue solid line; CTV1, orange color wash; PTV1, pink color wash.
similar to the previous description (21). SBRT boost treatments
were delivered with CyberKnife (Accuracy). The SBRT boost began
right after completion of WPRT and was administered in every-
the-other days. Each treatment day, prior to SBRT, patients were
asked to empty their bowels. Laxatives or glycerol ball enema were
allowed.
HORMONE THERAPY
Hormone therapy was administrated at the discretion of the treat-
ing physician. In this study, LH-RH agonists, anti-androgen agents,
or a combination were allowed for long-term use.
FOLLOW-UP AND TOXICITY ASSESSMENT
All patients were scheduled for follow-up 4 weeks after final
treatment, and then every 3 months thereafter. Acute and late
toxicities of gastrointestinal (GI) and genitourinary (GU) tracts
nature were assessed by Common Toxicity Criteria Adverse Effect
(CTCAE version 3.0) at every follow-up visit. Acute toxicity was
defined as occurring within 6 months of completing treatment,
and late toxicity as those events occurring later than 6 months.
PSA tests and self-administered IPSS quality of life (QoL) score
questionnaires (22) were performed every 3 months. Biochem-
ical failure was defined using the Phoenix definition. All post-
treatment time intervals were calculated from the time of radi-
ation therapy completion. Biochemical recurrence-free survival
was estimated by Kaplan–Meier survival curve (SPSS, Version 19,
IBM, USA).
RESULTS
PATIENT CHARACTERISTICS AND FOLLOW-UP
A total of 41 consecutive patients were analyzed. The median
age was 72.5 years (range, 61–83 years). Patient characteristics are
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summarized in Table 1. The median follow-up was 42 months
(range, 1.5–58 months). One patient died from liver failure
induced by hypersensitivity to anti-androgen agents. The other
two patients died from distant metastasis after biochemical
failures.
Twenty-eight patients (68.3%) received anti-androgen mono-
hormone therapy, ten patients (24.4%) received LH-RH agonist-
based hormone therapy, and three patients (7.3%) refused any
hormone therapy.
TOXICITY PROFILE AND QUALITY OF LIFE
Acute toxicity
Acute and late GI and GU toxicity profiles were minimal
(Figure 3). The most common GU toxicities were frequency,
urgency, and urinary obstructive symptoms. No grade 3 acute GU
or GI tract toxicity was noted. During the radiation therapy, 27%
Table 1 | Patient characteristics.
Characteristics n (%)
Age (mean) 72.5 (range, 61–83)
Primary t stage
T1a–c 1(2.4%)
T2a–c 23(56.1%)
T3a 8(19.5%)
T3b 9(21%)
Clinical nodal status
N0 41(100%)
Gleason score
≤6 10(24.4%)
=7 14(34.1%)
≥8 17(41.5%)
PSA level (ng/ml)
Median 44.15 (range, 4.51–250.32)
≤10 7(17.1%)
10–20 9(21.9%)
>20 25(61.0%)
NCCN risk group
High-risk 32(78.1%)
Very high-risk 9(21.9%)
Hormone therapy
Neoadjuvant 22(53.7%)
Concurrent 16(39.0%)
No 3(7.3%)
IPSSa (Pre-treatment)
0–7 13(33.3%)
8–19 16(41.0%)
20–35 10(25.7%)
IIEFa (Pre-treatment)
0 21(53.8%)
≤21 38(97.4%)
≥22 1(2.6%)
IPSS, international prostate symptom score; IEFF, international index of erectile
function questionnaire.
aOnly 39 patients completed the questionnaires.
of the patients had grade 2 acute GU toxicity and 12% had grade 2
acute GI toxicity. The course of the symptoms peaked at 1–2 weeks
following the completion of the treatment. Most of toxicity scores
had returned to baseline within 3 months.
Late toxicity
Fluctuating late GU grade 2 toxicities were observed in 3–11% of
patients during the follow-up. There were no late grade 3 GU tox-
icity events. No late GI grade 2 or higher toxicities were observed
at the last follow-up of the patients. Change in potency after
radiotherapy was difficult to assess in the current study for two
reasons. One was the impact of long-term hormone therapy. Most
of the patients (97.4%) had no sexual activity or some erectile
dysfunction before the treatment (Table 1).
Quality of life
In Table 2, we summarize the patient self-reported urinary QOL
score at baseline, at 3 months, 1 year, and 2 years after comple-
tion of SBRT. Only one patient reported “terrible” (QOL score
6) urinary symptoms at 6 months. This patient was also “mostly
dissatisfied/unhappy” (QOL score 4–5) at baseline. We noted that,
although the urinary QOL scores deteriorated between 6th and
12th months, they recovered and in fact improved over baseline at
1 and 2 years, with more than 80% of the patients reporting QOL
scores below 3.
BIOCHEMICAL FAILURE-FREE SURVIVAL AND PSA RESPONSE
Mean PSA level before the treatment was 44.18 ng/ml. Mean
PSA level (excluding biochemical failures) at 3, 6, 12, 18, and
24 months was 0.94, 0.44, 0.13, 0.12, and 0.05 ng/ml, respec-
tively. No obvious PSA bounce of >0.2 ng/ml was observed since
long-term hormone therapy was applied. Only some mild ele-
vation of PSA (>0.2 ng/ml) was observed after the cessation of
long-term hormone therapy. The estimated 4-year overall sur-
vival and biochemical failure-free survival were 92.2 and 91.9%,
respectively (Figure 4). Three biochemical failures were observed.
All three biochemical failures occurred between 3 and 6 months
post-treatment. Only one patient received prostate biopsy that
showed negative founding, who then salvage successfully by weekly
Taxane-based chemotherapy. Two other patients with bone metas-
tasis evidence had not undergone prostate biopsy. The PSA level
of these two patients continued to flare up to more 1000 ng/ml
even under different systemic treatments; one patient died and
one patient was lost.
DISCUSSION
ENCOURAGING RESULTS
The development of SBRT boost has been based on the clinical suc-
cess of HDR brachytherapy boost. Several studies of HDR boost
in conjunction of EBRT have reported 5-year biochemical control
rates of 61–83% for high-risk prostate cancer (15–19, 23). HDR
brachytherapy has led to a 3–10% late grade 3 GU toxicities and 3–
7% of the patients who underwent HDR brachytherapy boost have
experienced urethral stricture (15, 16, 18, 19, 23). Acute and late
rectal toxicity rates have been minimal following HDR brachyther-
apy boost. Grade 1 and grade 2 late GI toxicities have been reported
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FIGURE 3 |Toxicity profile with time flame of the patients who underwent whole pelvis radiotherapy with stereotactic body radiotherapy boost.
(A) The genitourinary tract toxicity profiles and (B) the gastrointestinal toxicity profile.
to be in the range of 2–17% (16, 18, 19, 23). Grade 3 or 4 late GI
toxicities have been mentioned in the range of 0.5–1% (15, 19).
In the current study, the outcome of high-risk patients treated
with WPRT, SBRT boost, and long-term hormone therapy was
comparable to the above HDR boost series with the 4-year bio-
chemical failure-free survival at 91.9%. There were no grade 3 or
higher GU and no grade 2 or higher late GI toxicity events. And
there were no urethral strictures at last follow-up.
Several studies have been published with use of SBRT as boost
to WPRT in high-risk patients with the similar results (24–26).
Therefore, SBRT boost is an attractive established option for dose
escalation with some advantages to brachytherapy boost: (1) non-
invasive procedure, (2) no requirement of transperineal catheter
or urinary catheter, (3) no necessity for hospital admission, (4)
ability to deliver high doses safely to extraprostatic or seminal
vesicle invasion.
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Table 2 | Quality of life score.
IPSS QoL score Baseline (%) 1 month (%) 3 months (%) 6 months (%) 9 months (%) 12 months (%) 18 months (%) 24 months (%)
0–1 5.1 12.5 18.5 20.0 21.7 26.3 25.0 27.3
2–3 71.8 62.5 66.7 72.0 65.2 57.9 56.3 63.6
4–5 23.1 25.0 14.8 4.0 13.0 15.8 18.8 9.1
6 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0
IPSS QoL score, international prostate symptom score, quality of life score.
FIGURE 4 | Kaplan–Meier curves illustrate the survival of the patients who underwent whole pelvis radiotherapy with stereotactic body radiotherapy
boost, including (A) overall survival; 4-year overall survival, 92.2% (B) biochemical recurrence-free survival; 4-year biochemical recurrence-free
survival, 91.9%.
PROSTATE-ONLY SBRT FOR HIGH-RISK PATIENTS
Even though hypofractionation to the prostate only is now
accepted as a therapeutic option for high-risk patients, (27) a sin-
gle institutional data (28) showed no significant difference in the
biochemical control rate (6-year biochemical disease-free survival,
69%) for high-risk patients either treated with prostate-only SBRT
or WPRT with SBRT boost. Some 55.7% of the patients received
androgen deprivation therapy (ADT). A pooled analysis of multi-
institutional prospective trials (29) showed the 5-year biochemical
relapse-free survival rate at 95, 83, and 78% for Gleason score≤6, 7,
and ≥8, respectively, and 95, 84, and 81% for low-, intermediate-,
and high-risk patients, respectively. Only 38% of the high-risk
patients were administered ADT.
Our results demonstrate a high biochemical control rate for
high-risk patients, which is even higher than those with prostate-
only SBRT or WPRT with SBRT boost studies. The possible reasons
are (1) SBRT boost, (2)WPRT, and (3) long-term hormone ther-
apy. This three-modality approach delivers such a potent therapy
to the prostate, the extraprostatic extension, and seminal vesicles,
thereby increasing the probability of eradicating all the local and
regional disease and hormone therapy may play a role in elimi-
nating occult systemic disease and enhancing synergistic effects to
radiation.
RATIONALE FOR PELVIC NODE RT
Whether or not the elective irradiation of pelvic nodes provides
any benefit as compared to treating the prostate only has been a
longstanding therapeutic dilemma (30, 31). RTOG 94-13 initially
showed that NHT with WPRT improved progression-free survival
(PFS) and PSA relapse-free survival than prostate-only fields (30).
The updated results of RTOG 94-13, however, showed diminished
significance in the improvement in PFS with only a trend in favor
of WP with NHT. These collective findings were interpreted to
show an unexpected biologic interaction between the timing of
hormone therapy and WPRT and concluded the biologic benefit
of WPRT with NHT for high-risk prostate cancer (32). However,
that conclusion might not be suitable to apply to the current status
of prostate cancer risk distribution in PSA screening era (33).
On the other hand, two systematic reviews (34, 35) from
surgical viewpoints have suggested that extended pelvic lymph-
node dissection could improve survival by eliminating regional
micrometastatic disease.
In the current study, most patients had high tumor burden
(high PSA level, more advanced T stage, higher Gleason score),
which might lead to higher rate of microscopic local/regional
extension. Hence,WPRT was important in enhancing biochemical
control rate in the current study.
COMPARING TOXICITY WITH A WPRT AND SBRT BOOST STUDY
In a WPRT and SBRT boost study (28), Katz et al. observed slightly
higher GU toxicities in the WPRT with SBRT boost group than in
the SBRT monotherapy group for high-risk patient (grade 2, 7.8
vs. 2.3%; grade 3, 3.9 vs. 2.3%). The WPRT with SBRT boost group
also had a higher rate of grade 2 GI toxicity (13.3 vs. 0%).
Frontiers in Oncology | Radiation Oncology October 2014 | Volume 4 | Article 278 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lin et al. SBRT boost for high-risk prostate cancer
We also had a similar observation comparing SBRT monother-
apy for low- and intermediate-risk patients with WPRT and SBRT
boost for high-risk patients in our institutional data (36). In the
current study, we did not observe any acute or late grade 3 toxicity
of either GI or GU tract. There were less than 11% late grade 2 GU
toxicity and 0% of late grade 2 GI toxicity. This could be the result
of the application of modern radiotherapy advances. We used vol-
umetric modulated arc therapy technique for WPRT rather than
3D-conformal radiotherapy or 4-field box technique, followed by
real time-tracking SBRT system. Hence, we were able to reduce
the dose received by urinary bladder and rectum to prevent further
toxicity (Figures 1 and 2). The advance of radiotherapy technology
made WPBT effective and safe.
ROLE OF HORMONE THERAPY
The role of ADT with definitive radiotherapy for high-risk local-
ized prostate cancer is well established from randomized clinical
trials and meta-analyses (37–40). A meta-analysis (37) based on
randomized clinical trials of RT alone vs. RT with ADT showed
improvement in all survival outcome measurements. In another
meta-analysis comparing short vs. longer duration of ADT, it con-
cluded that a longer course of ADT was superior to the shorter
course (38).
Taking into account the current stage migration from PSA
screening, RT dose escalation, and the morbidities of long-term
ADT (e.g., cardiovascular risk, endocrine detrition, QoL, depres-
sion, osteoporosis), there may be a little added therapeutic benefit
from it (28, 29, 41).
However, since the patients in the current study are from a
low-PSA-screening region and most of them had a higher tumor
burden and the most attending physicians prescribed long-term
hormone therapy for these patients. Most common regimen was
anti-androgen agents, which is not a standard monohormone
therapy agent considering the higher hepatotoxicity prevalence
in Taiwan (42). The current NCCN Asia consensus stated that
ADT was an effective treatment for prostate cancer patients with
less significant comorbidities in Asia (43). Therefore, we shifted
our hormone therapy regimen to short-term anti-androgen agents
(2–6 months) in combination with long-term LH-RH agonists for
2 years.
All in all, our data contain the largest cohort of SBRT boost for
high-risk disease in Asia, which showed excellent disease control
rate and relatively low rate of acute and late toxicity profiles. But
it should be cautioned that all these modalities might cause some
side effects. How to modify and optimize these three modalities
will depend on the results of the ongoing clinical trials.
In conclusion, whole pelvis irradiation combined with SBRT
boost is an attractive treatment option for patients with high-
risk disease, with the potential to increase biological dose and
thus improve biochemical control, without increasing toxicity and,
from a practical viewpoint, reducing overall treatment time. Con-
tinued accrual and follow-up would be necessary to confirm the
biochemical control rate and the toxicity profiles.
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